US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 2019 World Conference on Lung Cancer (WCLC) in Barcelona, Spain (07 - 10 September 2019).The two presentations will outline BerGenBio’s Phase II clinical trial (BGB008, NCT03184571) with bemcentinib and

BerGenBio ASA: Results for the Second Quarter and First Half 2019

· Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy · Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those with low or no PD-L1 expression. · Recruitment completed for second stage Phase II bemcentinib and KEYTRUDA® combo trial in patients with advanced NSCLC (BGB008) · Private placement completed,

BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy

· Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June · Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy shows significant efficacy · Preliminary responses reported in 6/14 (43%) patients, with CR/CRi in 4/14 (29%) patients; this is substantially higher than previously observed/historical benchmarks in single-agent cytarabine (low-dose chemotherapy) · Median relapse-free survival 7.9 months in CR/CRi patients (

BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019

· Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising efficacy · 6 out of 13 (46%) patients receiving LDAC combination achieved an Overall Response Rate (ORR) of 46% · 3 out of 12 evaluable patients receiving decitabine combination achieved an ORR of 25% · ORR significantly higher than previously observed/historical benchmarks in single-agent cytarabineChicago, USA, 03 June 2019 – BerGenBio ASA (OSE:BGBIO) today presents data showing significant efficacy in Phase II clinical trials (

BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in pts with advanced NSCLC at ASCO 2019

· Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy · Promising clinical activity continues to be seen, particularly in patients with AXL positive tumours including those with low or no PD-L1 expressionChicago, USA, 02 June 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today presents updated data from its Phase II

BerGenBio ASA: Invitation to ASCO Update Call

Bergen, Norway, 31 May 2019 – BerGenBio ASA (OSE:BGBIO), will share its latest updates and data on an investor call on 4 June 2019, during the annual American Society of Clinical Oncology (ASCO) meeting. BerGenBio’s senior management team will be hosting the call at 15:30 CET.Dial-in details are: · Standard International Dial-In: +44 (0) 2071 928000 · United States Dial-In: 16315107495 · Participant Code: 4352428 The call will focus on two peer reviewed abstracts on Phase II clinical data with bemcentinib in the treatment of Non-Small Cell Lung Cancer and Acute Myeloid

BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 · Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety, response rates and overall survival · Acute Myeloid Leukaemia (AML) trial of bemcentinib in combination with low dose AraC chemotherapy or decitabine reported safety and rapid, durable complete response ratesBergen, Norway, 15 May 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase

BerGenBio completes recruitment into second stage of Phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC

· Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) · First stage previously met efficacy endpoint · Second stage enrolled a further 24 patients for a total of 48; efficacy and biomarker data updates expected at medical conferences during 2019Bergen, Norway, 08 May 2019 – BerGenBio ASA (OSE: BGBIO) announces that it has completed enrolment into the second stage of its Phase II trial (BGBC008, Cohort A NCT03184571) evaluating the Company’s selective AXL inhibitor bemcentinib in combination with MSD’

BerGenBio ASA: Results for the First Quarter 2019

· Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia · Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® · Anti-AXL antibody, BGB149, commenced phase I safety and pharmacokinetic clinical trial.Bergen, Norway, 08 May 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer

BerGenBio ASA: Invitation to First Quarter Presentation and Webcast

Bergen, Norway, 24 April 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter on Wednesday, 8 May 2019. A presentation by BerGenBio’s senior management team will take place at 10:00 am CET at: Felix Konferansesenter,Bryggetorget 3,0125 Oslo. The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished. The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial

BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA · Accepted for presentation at ASCO in June 2019Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present new interim clinical and biomarker data from its extensive Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, at the 2019 annual meeting of the American

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference

Bergen, Norway, April 09 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers, announces that Richard Godfrey, BerGenBio’s Chief Executive Officer, will present an overview of the Company at the H.C. Wainwright Global Life Sciences Conference today, April 9, 2019.Date: Tuesday, April 9, 2019Time: 09:10 AM BST Location: JW Marriott Grosvenor House, London, UK The presentation

BerGenBio extends Phase II trial with bemcentinib and KEYTRUDA® in NSCLC to include patients with disease progression on immune checkpoint inhibitor therapy

· First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy · New cohort added under existing collaborative agreement with Merck assessing the combination in previously treated advanced NSCLC · Decision to extend driven by encouraging preclinical data and high unmet need for treatment options after anti-PD(L)1 failureBergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in an

BerGenBio: Preclinical data presented at AACR reinforces bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance

· Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL’s role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR · Selective AXL inhibitor, bemcentinib, shown to reverse AXL’s effects, thus acting synergistically with immune cells and anti-cancer therapies · Data further strengthens broad development opportunities for bemcentinib both as a monotherapy, and in combinations, in a broad spectrum of cancersBergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage

BerGenBio: Bemcentinib in combination with low-dose chemotherapy achieves efficacy endpoint in AML patients

Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy Bemcentinib + low-dose cytarabine (LDAC) achieves efficacy endpoint, warrants further investigation · Three out of 10 evaluable patients (30%) reported Complete Responses (CR/CRi) · Responses occurred early, improved over time and included poor risk, previously treated patients · No overlapping or new toxicities observed Meanwhile, Company will proceed with late-stage bemcentinib monotherapy trial in R/R AML patients, expected for H2 2019; monotherapy

BerGenBio ASA publishes Annual Report for 2018

Bergen, Norway, 20 February 2019 – The Board of Directors of BerGenBio ASA (OSE:BGBIO) has today approved the Company's Annual Report for 2018 including the complete 2018 Annual Accounts with notes. The report is attached and available for download at www.bergenbio.com in the section: Investors/Financial Reports. -End-About BerGenBio ASA  BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers.  The company’s proprietary lead candidate, bemcentinib, is

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018

Important progress made in 2018: · PoC for bemcentinib reported in multiple cancer indications · AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 · Increasing confidence in bemcentinib safety profile with more than 250 patients dosedBergen, Norway, 12 February 2019 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2018. A presentation of the results by

BerGenBio announces start of phase I trial evaluating ADCT-601, a novel anti-AXL ADC, in patients with advanced solid tumours

· ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate (ADC) development · Phase I dose escalation and expansion trial will evaluate ADCT-601 in 75 cancer patients · ADCT-601 is BerGenBio’s third clinical candidate targeting AXLBergen, Norway, January 21 2019 - BerGenBio ASA (OSE:BGBIO), announces that the first patient has been dosed in a phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour efficacy of ADCT-601, an AXL-targeting antibody drug conjugate (ADC), in patients

BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149

· BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development · BGB149 is BerGenBio’s second novel clinical candidate targeting AXL · Phase I study will investigate safety and pharmacokinetics in healthy volunteersBergen, Norway, January 9 2019 - BerGenBio ASA (OSE:BGBIO),a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers, announces today that the first subject has been dosed in a Phase I

BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS

· Phase II monotherapy study of bemcentinib in high-risk MDS & AML · Will enrol up to 43 patients at leading MDS centres across Europe · Investigator sponsored trial led by Prof. Uwe PlatzbeckerBergen, Norway, Jan 4th 2019 - BerGenBio ASA (OSE: BGBIO), announces that the first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who have failed first-line treatment with hypomethylating agents. The trial may also enrol a proportion of

BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB’s 9th Annual Nordic Healthcare Conference

· Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia · AXL biomarker correlation supports bemcentinib’s proposed MoA, potential for Companion Diagnostic · Significant milestones expected over next 12 monthsBergen, Norway, 12 Dec 2018 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the Company will be presenting key results from its Phase II clinical programme with

BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH

· 43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) · Phase II trial continues in combination with chemotherapeutics in first line AML · Bemcentinib with decitabine cohort has completed recruitment, data will be submitted for presentation at upcoming medical congressBergen, Norway, 3 Dec 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented a

BerGenBio ASA: Results for the Third Quarter 2018

· Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients · Additional NSCLC data: Bemcentinib/TARCEVA phase II combination trial in first line EGFRm patients reported that median PFS has surpassed that of TARCEVA monotherapy, encouraging efficacy reported in combination trial with docetaxel in later line patients · Pipeline update: IND filed for AXL antibody BGB149Bergen, Norway, 13 November 2018 – BerGenBio ASA (OSE:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media